At SLAS Europe, TTP's Jon Wingfield and Wenshu Xu discuss how artificial intelligence is changing drug discovery and why accelerating Design-Make-Test-Analyse (DMTA) requires more than better algorithms. From automation and data-driven decision-making to overcoming bottlenecks in synthesis, purification and testing, they explore how the next generation of integrated workflows will enable faster, smarter drug discovery and better experimental outcomes.
Explore the full DMTA campaign to learn how TTP is helping pharmaceutical and biotechnology companies build faster, more integrated drug discovery workflows through advances in automation, assay technologies, purification and workflow design.
About TTP's Drug Discovery Tools Team
TTP helps pharmaceutical and biotechnology companies accelerate drug discovery by removing bottlenecks across the Design-Make-Test-Analyse (DMTA) cycle.
Our Drug Discovery Tools team develops bespoke technologies that enable faster experimentation, higher-quality data and more efficient decision-making. Combining expertise in biology, chemistry, automation, microfluidics, software and instrumentation, we help clients solve complex challenges spanning synthesis, purification, screening, organoid systems, assay development and integrated laboratory workflows.
From targeted workflow improvements to entirely new discovery platforms, we work with clients to increase DMTA iteration velocity and unlock the full potential of AI-enabled drug discovery.
